Journal of Clinical Oncology · 2007 · 10 citations · 0 references
MedicineOncologyPharmacologyCancer PharmacologyOncology PharmacotherapyThoracic OncologyLung CancerLung Cancer PharmacotherapyMonoclonal Antibody InfusionNon-small Cell Lung Cancer Adjuvant TherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentSquamous Cell Carcinoma HistologyTumor Vasculature Targeting
18046 Background: Bevacizumab (BEV) is a monoclonal antibody against VEGF approved for treatment of advanced NSCLC in the 1 st line setting. BEV is being evaluated in other settings in NSCLC (2 nd line, adjuvant). BEV is associated with a distinct toxicity profile including hemorrhage, delayed wound healing, viscus perforation, hypertension (HTN), and thrombosis which limits its use. At the VA medical center, we noticed poor accrual to trials with BEV. We retrospectively studied all patients diagnosed with NSCLC in the past 3 years to identify the factors that would exclude patients from participating in clinical trials with BEV. Methods: Patients were identified from our tumor registry and clinical data was reviewed. We used the exclusion criteria as per ECOG 4599 and an open industry sponsored trial (erlotinib ± BEV for 2 nd line NSCLC) as listed in the table below. Results: A total of 106 male veterans with stage 4 NSCLC were identified with a median age of 72 years. Patients with squamous predominant histology (n=26) were excluded. Of the remaining 80 patients evaluated for use of BEV, 72 patients (90%) met 1 or more exclusion criteria. The following table displays the breakdown of exclusion criteria both non-specific and specific to BEV. Conclusions: Elderly veterans with NSCLC have multiple co-morbidities precluding use of cytotoxic chemotherapy. Use of BEV is further limited in this population. There is a need for agents with a favorable toxicity profile in the treatment of NSCLC. Clinical trials specific to the needs of this group of patients with poor PS and multiple co-morbidities are needed to improve participation and to offer newer therapies to the elderly veteran with lung cancer. [Table: see text] No significant financial relationships to disclose.